RÉSUMÉ
Diabetic foot infection imposes a significant burden and is the major cause of nontraumatic limb amputation. Adequate patient management with effective antibiotic therapy is crucial.This retrospective cohort study aimed to characterize the microbiology and resistance patterns of moderate to severe neuropathic diabetic foot infection in patients hospitalized at a tertiary referral hospital between January 2020 and June 2023. Deep tissue specimens from ulcers were collected for culture.Sixty inpatients were included (62% male, mean age 59.1 ± 11.5 years). Osteomyelitis was present in 90% of the patients. Among 102 microorganisms (average of 1.91 ± 1.25 pathogens per patient), 60.8% were gram-positive bacteria, 31.4% were gram-negative, 3.92% were anaerobic bacteria, and 3.92% were fungi. Staphylococcus aureus (19%) and Enterococcus faecium (17%) were the most common. Pseudomonas aeruginosa (8%) and bacteria of the Enterobacterales family (24%) accounted for all the isolated gram-negative bacteria. Sixteen percent of Staphylococcus aureus and 67% of coagulase-negative Staphylococci were resistant to methicillin. Resistance to ampicillin was found in 11% of Enterococci. All Pseudomonas aeruginosa isolates were sensitive to piperacillin-tazobactam, ceftazidime, or cefepime. Among the Enterobacterales, resistance rates were 35% for piperacillin-tazobactam, 38% for ceftazidime, 21% for cefepime, and 13% for carbapenems.Although the prevalence of methicillin-resistant staphylococci was lower than that in other studies, carbapenem resistance among gram-negative bacteria warrants attention. This study highlights the importance of understanding local epidemiology for effective diabetic foot infection management and resistance mitigation.
Sujet(s)
Antibactériens , Pied diabétique , Centres de soins tertiaires , Humains , Pied diabétique/microbiologie , Pied diabétique/traitement médicamenteux , Mâle , Adulte d'âge moyen , Études rétrospectives , Centres de soins tertiaires/statistiques et données numériques , Femelle , Sujet âgé , Antibactériens/usage thérapeutique , Antibactériens/pharmacologie , Portugal/épidémiologie , Tests de sensibilité microbienne , Ostéomyélite/microbiologie , Ostéomyélite/traitement médicamenteux , Bactéries à Gram négatif/effets des médicaments et des substances chimiques , Bactéries à Gram négatif/isolement et purification , Bactéries à Gram négatif/classification , Bactéries/isolement et purification , Bactéries/classification , Bactéries/effets des médicaments et des substances chimiques , Bactéries/génétique , Bactéries à Gram positif/effets des médicaments et des substances chimiques , Bactéries à Gram positif/isolement et purification , Bactéries à Gram positif/classificationRÉSUMÉ
The main objective of this work was to investigate the mechanism of Astragalus aqueous extract ulcer healing in diabetic foot model rats through the hypoxia-inducible factor 1-alpha (HIF-1É)/vascular endothelial growth factor (VEGF) signalling pathway. Fifty specific-pathogen-free male Sprague Dawley rats were divided into blank (A), model control (B), Astragalus extract (C) and mupirocin (D) treatment groups. Group A received a regular diet, whereas the other groups received a high-fat/high-sugar diet and intraperitoneal streptozotocin injections to induce diabetes. Diabetic foot ulcers were created via skin excision. Subsequently, ulcers were debrided daily. Groups B, C and D received wet saline gauze, wet gauze with Astragalus extract and gauze with mupirocin, respectively, on the affected area. Group A received no treatment. After 14 days, the rats were assessed for ulcer healing and general condition. Immunohistochemistry was used to detect HIF-1É and VEGF levels in the dorsalis pedis artery, and ELISA was used to determine serum IL-6 and CRP levels. The results revealed that Groups C and D had significantly faster ulcer healing compared with Group B (p < 0.01), and ulcer healing was faster in Group C than in Group D (p < 0.01). Group C exhibited notably higher HIF-1É and VEGF protein expression levels compared with Groups B and D (p < 0.01). IL-6 and CRP expression levels in Groups C and D were significantly lower than those in Group B (p < 0.01). In summary, Astragalus aqueous extract effectively treats diabetic foot ulcers by up-regulating HIF-1É and VEGF expression, activating the HIF-1É/VEGF pathway, improving local tissue ischaemia and hypoxia, promoting collateral circulation and enhancing dorsalis pedis artery formation, thereby accelerating ulcer repair in diabetic rats.
Sujet(s)
Astragalus , Pied diabétique , Sous-unité alpha du facteur-1 induit par l'hypoxie , Extraits de plantes , Rat Sprague-Dawley , Transduction du signal , Facteur de croissance endothéliale vasculaire de type A , Cicatrisation de plaie , Animaux , Pied diabétique/traitement médicamenteux , Pied diabétique/métabolisme , Mâle , Facteur de croissance endothéliale vasculaire de type A/métabolisme , Sous-unité alpha du facteur-1 induit par l'hypoxie/métabolisme , Transduction du signal/effets des médicaments et des substances chimiques , Extraits de plantes/pharmacologie , Extraits de plantes/usage thérapeutique , Astragalus/composition chimique , Cicatrisation de plaie/effets des médicaments et des substances chimiques , Diabète expérimental/traitement médicamenteux , Diabète expérimental/métabolisme , Diabète expérimental/complications , Rats , Interleukine-6/métabolisme , Interleukine-6/sang , Protéine C-réactive/métabolismeRÉSUMÉ
Colostrum is gaining popularity in cosmetic products. The present study compared the composition and selected biological properties of colostrum from Polish sheep (colostrum 1) and Swiss sheep (colostrum 2), particularly those that can affect healthy or diseased skin. The antioxidant activity of the colostrums was measured using ABTS and DPPH assays. The effect on the proliferation of human skin fibroblasts, neonatal epidermal keratinocytes, and human diabetic fibroblast (dHF) cells isolated from diabetic foot ulcers was also assayed in vitro by MTT and Presto Blue tests, respectively. The colostrum simulated dHF cell proliferation by up to 115.4%. The highest used concentration of colostrum 1 stimulated normal fibroblast proliferation by 191.2% (24 h) and 222.2% (48 h). Both colostrums inhibited epidermal keratinocyte viability. The influence of the colostrums on the expression of genes related to proliferation (Ki67) and immune response (IL-6, PTGS-2, TSG-6) in dHF cells were compared. Colostrum 1 increased the rate of wound closure (scar test). Analysis of total fat, protein and fatty acid content found the Polish colostrum to be a richer source of fat than the Swiss colostrum, which contained a larger amount of protein. Both colostrums exhibit properties that suggest they could be effective components in cosmetic or medicinal formulations for skin care, especially supporting its regeneration, rejuvenation, and wound healing.
Sujet(s)
Prolifération cellulaire , Colostrum , Fibroblastes , Kératinocytes , Hygiène de la peau , Colostrum/composition chimique , Animaux , Ovis , Humains , Prolifération cellulaire/effets des médicaments et des substances chimiques , Fibroblastes/métabolisme , Fibroblastes/effets des médicaments et des substances chimiques , Kératinocytes/effets des médicaments et des substances chimiques , Kératinocytes/métabolisme , Hygiène de la peau/méthodes , Antioxydants/pharmacologie , Femelle , Cicatrisation de plaie/effets des médicaments et des substances chimiques , Peau/métabolisme , Survie cellulaire/effets des médicaments et des substances chimiques , Grossesse , Administration par voie topique , Pied diabétique/thérapie , Pied diabétique/traitement médicamenteux , Pied diabétique/métabolisme , Cellules cultivéesRÉSUMÉ
The complex microenvironment of diabetic wounds often hinders the healing process, ultimately leading to the formation of diabetic foot ulcers and even death. Dual monitoring and treatment of wounds can significantly reduce the incidence of such cases. Herein, a multifunctional Janus membrane (3D chitosan sponge-ZE/polycaprolactone nanofibers-ZP) was developed by incorporating the zinc metal-organic framework, europium metal-organic framework, and phenol red into nanofibers for diabetic wound monitoring and treatment. The directional water transport capacity of the resulting Janus membrane allows for unidirectional and irreversible drainage of wound exudate, and the multifunctional Janus membrane creates up to a 99% antibacterial environment, both of which can treat wounds. Moreover, the pH (5-8) and H2O2 (0.00-0.80 µM) levels of the wound can be monitored using the color-changing property of phenol red and the fluorescence characteristic of Eu-MOF on the obtained membrane, respectively. The healing stages of the wound can also be monitored by analyzing the RGB values of the targeted membrane images. This design can more accurately reflect the wound state and treat the wound to reduce bacterial infection and accelerate wound healing, which has been demonstrated in in vivo experiments. The results provide an important basis for early intervention in diabetic patients.
Sujet(s)
Antibactériens , Réseaux organométalliques , Nanofibres , Cicatrisation de plaie , Cicatrisation de plaie/effets des médicaments et des substances chimiques , Animaux , Nanofibres/composition chimique , Nanofibres/usage thérapeutique , Réseaux organométalliques/composition chimique , Réseaux organométalliques/pharmacologie , Antibactériens/composition chimique , Antibactériens/pharmacologie , Polyesters/composition chimique , Chitosane/composition chimique , Zinc/composition chimique , Phénolsulfonephtaléine/composition chimique , Europium/composition chimique , Souris , Humains , Membrane artificielle , Peroxyde d'hydrogène/composition chimique , Diabète expérimental/traitement médicamenteux , Pied diabétique/traitement médicamenteux , Pied diabétique/anatomopathologie , Staphylococcus aureus/effets des médicaments et des substances chimiquesRÉSUMÉ
In proper skin healing, inflammation will stop once the harmful microbes are removed. However, an excess and prolongation of inflammation can result in delayed healing. Thus, interventions that can limit the amount of inflammation can help promote wound healing. The use of olive oil in wound therapy has been of great interest. Herein, we will review studies that investigated the use of olive oil on diabetic foot ulcers, pressure ulcers, perineal ulcers, and chronic ulcers.
Sujet(s)
Huile d'olive , Cicatrisation de plaie , Huile d'olive/pharmacologie , Huile d'olive/administration et posologie , Humains , Cicatrisation de plaie/effets des médicaments et des substances chimiques , Ulcère cutané/thérapie , Ulcère cutané/traitement médicamenteux , Pied diabétique/traitement médicamenteux , Pied diabétique/thérapie , Escarre/traitement médicamenteux , Escarre/thérapieRÉSUMÉ
BACKGROUND: Diabetic foot syndrome is defined as the presence of a diabetic foot ulcer (DFU) associated with neuropathy, peripheral artery disease and infection. While the use of antimicrobials in the treatment of DFU infection remains a mainstay, the choice of antimicrobial remains problematic owing to the presence of multidrug-resistant polymicrobial infections. In the South African public healthcare sector, the treatment of DFUs is based on the Standard Treatment Guidelines (STGs) and the Essential Drug List. These guidelines are developed using evidence-based medicine and are based on global susceptibility patterns rather than local susceptibility data, and may not provide the most appropriate treatment options. OBJECTIVES: To determine the antimicrobial susceptibility patterns of DFUs isolated from patients visiting selected Gauteng provincial public hospitals in order to determine a clinically effective treatment protocol for the management of these infections. METHODS: Sample swabs were taken from 51 DFUs using the Levine method. Each sample swab was spread onto blood agar plates, and thereafter individual pathogens were isolated. The antimicrobial susceptibility patterns of all isolated pathogens were determined using zone of inhibition measurements. Pathogens were grouped according to macromorphological characteristics as well as susceptibility patterns, and a representative isolate from each group was then identified. RESULTS: A total of 51 DFU ulcer swabs from 45 patients were included in the study. From the sample swabs, a total of 445 pathogens were isolated. The most effective antimicrobial was found to be gentamicin, followed by ciprofloxacin. Amoxicillin/clavulanic acid, the first-line treatment according to the STGs, was found to be ineffective for many of the isolated pathogens. The most commonly isolated pathogens were Proteus mirabilis, Enterococcus faecalis and Pseudomonas aeruginosa. CONCLUSION: These findings demonstrate the urgent need to reassess the STGs and base treatment plans on local epidemiological data. This study provides valuable data on common causative pathogens in DFU infections, as well as the resistance patterns of these pathogens, forming a baseline on which to base future DFU treatment plans.
Sujet(s)
Antibactériens , Pied diabétique , Tests de sensibilité microbienne , Humains , Pied diabétique/microbiologie , Pied diabétique/traitement médicamenteux , République d'Afrique du Sud/épidémiologie , Antibactériens/usage thérapeutique , Mâle , Femelle , Adulte d'âge moyen , Secteur public , Sujet âgéSujet(s)
Benzoxazoles , Pied diabétique , Gangrène , Humains , Pied diabétique/traitement médicamenteux , Pied diabétique/complications , Gangrène/étiologie , Benzoxazoles/usage thérapeutique , Butyrates/pharmacologie , Butyrates/usage thérapeutique , Mâle , Femelle , Adulte d'âge moyen , Résultat thérapeutiqueRÉSUMÉ
AIM: To investigate the effect of dipeptidyl peptidase-4 inhibitors (DPP4-Is) and glucagon-like peptide-1 receptor agonists (GLP1-RAs) on diabetic foot ulcer (DFU) and DFU-related outcomes (lower limb amputation [LLA], DFU-related hospitalization and mortality). METHODS: We performed a cohort study with data from the Clinical Practice Research Datalink Aurum database with linkage to hospital data. We included people with type 2 diabetes starting treatment with metformin. Then we propensity score matched new users of DPP4-Is and sulphonylureas (N = 98 770), and new users of GLP1-RAs and insulin (N = 25 422). Cox proportional hazards models estimated the hazard ratios (HRs) for the outcomes. RESULTS: We observed a lower risk of DFU with both DPP4-I use versus sulphonylurea use (HR 0.88, 95% confidence interval [CI]: 0.79-0.97) and GLP1-RA use versus insulin use (HR 0.44, 95% CI: 0.32-0.60) for short-term exposure (≤ 400 days) and HR 0.74 (95% CI: 0.60-0.92) for long-term exposure (>400 days). Furthermore, the risks of hospitalization and mortality were lower with both DPP4-I use and GLP1-RA use. The risk of LLA was lower with GLP1-RA use. The results remained consistent across several sensitivity analyses. CONCLUSIONS: Incretin-based therapy was associated with a lower risk of DFU and DFU-related outcomes. This suggests benefits for the use of this treatment in people at risk of DFU.
Sujet(s)
Amputation chirurgicale , Diabète de type 2 , Pied diabétique , Inhibiteurs de la dipeptidyl-peptidase IV , Récepteur du peptide-1 similaire au glucagon , Hypoglycémiants , Incrétines , Humains , Pied diabétique/traitement médicamenteux , Pied diabétique/épidémiologie , Mâle , Femelle , Inhibiteurs de la dipeptidyl-peptidase IV/usage thérapeutique , Inhibiteurs de la dipeptidyl-peptidase IV/effets indésirables , Diabète de type 2/traitement médicamenteux , Diabète de type 2/complications , Incrétines/usage thérapeutique , Incrétines/effets indésirables , Adulte d'âge moyen , Sujet âgé , Amputation chirurgicale/statistiques et données numériques , Récepteur du peptide-1 similaire au glucagon/agonistes , Hypoglycémiants/usage thérapeutique , Hypoglycémiants/effets indésirables , Études de cohortes , Sulfonylurées/usage thérapeutique , Sulfonylurées/effets indésirables , Hospitalisation/statistiques et données numériques , Insuline/usage thérapeutique , Metformine/usage thérapeutique , Metformine/effets indésirables , Modèles des risques proportionnelsRÉSUMÉ
The re-epithelialization process gets severely dysregulated in chronic nonhealing diabetic foot ulcers/wounds. Keratinocyte growth factor (KGF or FGF-7) is the major modulator of the re-epithelialization process, which regulates the physiological phenotypes of cutaneous keratinocytes. The existing therapeutic strategies of growth factor administration have several limitations. To overcome these, we have designed a KGF-mimetic peptide (KGFp, 13mer) based on the receptor interaction sites in murine KGF. KGFp enhanced migration and transdifferentiation of mouse bone marrow-derived MSCs toward keratinocyte-like cells (KLCs). A significant increase in the expression of skin-specific markers Bnc1 (28.5-fold), Ck5 (14.6-fold), Ck14 (26.1-fold), Ck10 (187.7-fold), and epithelial markers EpCam (23.3-fold) and Cdh1 (64.2-fold) was associated with the activation of ERK1/2 and STAT3 molecular signaling in the KLCs. Further, to enhance the stability of KGFp in the wound microenvironment, it was conjugated to biocompatible 3D porous polymer scaffolds without compromising its active binding sites followed by chemical characterization using Fourier transform infrared spectroscopy, field-emission scanning electron microscopy, dynamic mechanical analysis, and thermogravimetry. In vitro evaluation of the KGFp-conjugated 3D polymer scaffolds revealed its potential for transdifferentiation of MSCs into KLCs. Transplantation of allogeneic MSCGFP using KGFp-conjugated 3D polymer scaffolds in chronic nonhealing type 2 diabetic wounds (db/db transgenic, 50-52 weeks old male mice) significantly enhanced re-epithelialization-mediated wound closure rate (79.3%) as compared to the control groups (Untransplanted -22.4%, MSCGFP-3D polymer scaffold -38.5%). Thus, KGFp-conjugated 3D porous polymer scaffolds drive the fate of the MSCs toward keratinocytes that may serve as potential stem cell delivery platform technology for tissue engineering and transplantation.
Sujet(s)
Facteur de croissance fibroblastique de type 7 , Kératinocytes , Structures d'échafaudage tissulaires , Animaux , Souris , Structures d'échafaudage tissulaires/composition chimique , Kératinocytes/effets des médicaments et des substances chimiques , Facteur de croissance fibroblastique de type 7/composition chimique , Facteur de croissance fibroblastique de type 7/pharmacologie , Porosité , Peptides/composition chimique , Peptides/pharmacologie , Cicatrisation de plaie/effets des médicaments et des substances chimiques , Peau/effets des médicaments et des substances chimiques , Peau/anatomopathologie , Polymères/composition chimique , Polymères/pharmacologie , Cellules souches mésenchymateuses/effets des médicaments et des substances chimiques , Cellules souches mésenchymateuses/cytologie , Cellules souches mésenchymateuses/métabolisme , Mâle , Régénération/effets des médicaments et des substances chimiques , Matériaux biomimétiques/composition chimique , Matériaux biomimétiques/pharmacologie , Pied diabétique/traitement médicamenteux , Pied diabétique/anatomopathologie , Pied diabétique/thérapie , HumainsSujet(s)
Antibactériens , Ciments osseux , Pied diabétique , Cicatrisation de plaie , rho-Associated Kinases , Pied diabétique/traitement médicamenteux , Cicatrisation de plaie/effets des médicaments et des substances chimiques , Humains , Antibactériens/usage thérapeutique , Ciments osseux/usage thérapeutique , Ciments osseux/pharmacologie , rho-Associated Kinases/métabolisme , Mâle , FemelleSujet(s)
Antibactériens , Ciments osseux , Pied diabétique , Cicatrisation de plaie , rho-Associated Kinases , Cicatrisation de plaie/effets des médicaments et des substances chimiques , Pied diabétique/traitement médicamenteux , Humains , Antibactériens/usage thérapeutique , Antibactériens/pharmacologie , rho-Associated Kinases/métabolisme , Ciments osseux/usage thérapeutique , Ciments osseux/pharmacologie , Mâle , Femelle , Adulte d'âge moyenRÉSUMÉ
INTRODUCTION: Diabetic foot ulcers (DFUs) are commonly contaminated with pathogenic organisms and precede most diabetes-related amputations. Antimicrobial dressings are used in the treatment of DFUs; however, recent guidelines do not support their use. There are no data describing the experience of antimicrobial dressing use among podiatrists in Aotearoa New Zealand (AoNZ). This study aimed to (i) determine which antimicrobial dressings podiatrists in AoNZ use for the management of diabetic foot ulcers; and (ii) determine what factors influence AoNZ podiatrists' use of antimicrobial dressing when managing DFUs. METHODS: An anonymous cross-sectional web-based survey was undertaken. Participants were AoNZ registered podiatrists who managed DFUs in their practice. The survey included questions relating to personal and professional demographic characteristics and DFU management and dressing practices. Descriptive statistics were computed to address the research aims. RESULTS: Responses from 43 AoNZ podiatrists were included. Participants reported both cadexomer iodine and silver dressings were the most common antimicrobial dressings used, with honey dressings being the least frequently used. The most influential factors in choosing antimicrobial dressings when managing DFUs were the presence of current infection, ulcer exudate and ability to prevent future infection. The least influential factors in choosing antimicrobial dressings when managing DFUs were patient preferences, cost of dressings and comfort of dressing/pain on removal. CONCLUSIONS: AoNZ podiatrists managing DFUs primarily use antimicrobial dressings containing cadexomer iodine or silver as active ingredients, while lower-cost options, such as honey and povidone iodine are less often used. Current recommendations highlight the lack of evidence to support positive outcomes from any particular antimicrobial dressing over another and advocate that exudate control, comfort and cost be prioritised in decision-making. As cost has been an increasing burden to our healthcare funding, clinicians and organisations may consider this before purchasing and stocking expensive dressings.
Sujet(s)
Bandages , Pied diabétique , Podologie , Types de pratiques des médecins , Humains , Pied diabétique/thérapie , Pied diabétique/traitement médicamenteux , Nouvelle-Zélande , Études transversales , Bandages/économie , Bandages/statistiques et données numériques , Podologie/statistiques et données numériques , Mâle , Femelle , Types de pratiques des médecins/statistiques et données numériques , Adulte d'âge moyen , Anti-infectieux/usage thérapeutique , Anti-infectieux/économie , Enquêtes et questionnaires , Adulte , MielRÉSUMÉ
AIM: To evaluate the impact of denosumab on (i) the incidence of type 2 diabetes (T2D), and (ii) long-term health outcomes (microvascular [neuropathy, retinopathy, nephropathy] and macrovascular [cardiovascular disease, cerebrovascular accident] complications, and all-cause mortality) in patients with T2D, before (iii) combining results with prior studies using meta-analysis. METHODS: A retrospective analysis of data in a large global federated database (TriNetX; Cambridge, MA) was conducted from 331 375 patients, without baseline T2D or cancer, prescribed either denosumab (treatment, n = 45 854) or bisphosphonates (control, n = 285 521), across 83 healthcare organizations. Propensity score matching (1:1) of confounders was undertaken that resulted in 45 851 in each cohort. Secondary analysis further evaluated the impact of denosumab on long-term health outcomes in patients with T2D. Additionally, we systematically searched prior literature that assessed the association between denosumab and T2D. Estimates were pooled using random-effects meta-analysis. Risk of bias and evidence quality were assessed using Cochrane-endorsed tools. RESULTS: Denosumab (vs. bisphosphonates) was associated with a lower risk of incident T2D over 5 years (hazard ratio 0.83 [95% confidence interval {CI} 0.78-0.88]). Secondary analysis showed significant risk reduction in all-cause mortality (0.79 [0.72-0.87]) and foot ulceration (0.67 [0.53-0.86]). Also, pooled results from four studies (three observational, one randomized controlled trial) following meta-analysis showed a reduced relative risk (RR [95% CI]) for incident T2D in patients prescribed denosumab (0.83 [0.79-0.87]) (I2 = 10.76%). CONCLUSIONS: This is the largest cohort study to show that denosumab treatment is associated with a reduced RR of incident T2D, as well as an associated reduced RR of all-cause mortality and microvascular complications, findings that may influence guideline development in the treatment of osteoporosis, particularly in patients who are at a high risk of T2D.
Sujet(s)
Agents de maintien de la densité osseuse , Dénosumab , Diabète de type 2 , Diphosphonates , Ostéoporose , Humains , Dénosumab/usage thérapeutique , Dénosumab/effets indésirables , Diabète de type 2/traitement médicamenteux , Diabète de type 2/complications , Diabète de type 2/mortalité , Incidence , Études rétrospectives , Agents de maintien de la densité osseuse/usage thérapeutique , Agents de maintien de la densité osseuse/effets indésirables , Femelle , Mâle , Ostéoporose/traitement médicamenteux , Ostéoporose/épidémiologie , Sujet âgé , Diphosphonates/usage thérapeutique , Adulte d'âge moyen , Pied diabétique/prévention et contrôle , Pied diabétique/épidémiologie , Pied diabétique/mortalité , Pied diabétique/traitement médicamenteux , Adulte , Études de cohortesRÉSUMÉ
Introduction: Diabetes mellitus is frequently associated with foot ulcers, which pose significant health risks and complications. Impaired wound healing in diabetic patients is attributed to multiple factors, including hyperglycemia, neuropathy, chronic inflammation, oxidative damage, and decreased vascularization. Rationale: To address these challenges, this project aims to develop bioactive, fast-dissolving nanofiber dressings composed of polyvinylpyrrolidone loaded with a combination of an antibiotic (moxifloxacin or fusidic acid) and anti-inflammatory drug (pirfenidone) using electrospinning technique to prevent the bacterial growth, reduce inflammation, and expedite wound healing in diabetic wounds. Results: The fabricated drug-loaded fibers exhibited diameters of 443 ± 67 nm for moxifloxacin/pirfenidone nanofibers and 488 ± 92 nm for fusidic acid/pirfenidone nanofibers. The encapsulation efficiency, drug loading and drug release studies for the moxifloxacin/pirfenidone nanofibers were found to be 70 ± 3% and 20 ± 1 µg/mg, respectively, for moxifloxacin, and 96 ± 6% and 28 ± 2 µg/mg, respectively, for pirfenidone, with a complete release of both drugs within 24 hours, whereas the fusidic acid/pirfenidone nanofibers were found to be 95 ± 6% and 28 ± 2 µg/mg, respectively, for fusidic acid and 102 ± 5% and 30 ± 2 µg/mg, respectively, for pirfenidone, with a release rate of 66% for fusidic acid and 80%, for pirfenidone after 24 hours. The efficacy of the prepared nanofiber formulations in accelerating wound healing was evaluated using an induced diabetic rat model. All tested formulations showed an earlier complete closure of the wound compared to the controls, which was also supported by the histopathological assessment. Notably, the combination of fusidic acid and pirfenidone nanofibers demonstrated wound healing acceleration on day 8, earlier than all tested groups. Conclusion: These findings highlight the potential of the drug-loaded nanofibrous system as a promising medicated wound dressing for diabetic foot applications.
Sujet(s)
Antibactériens , Bandages , Pied diabétique , Libération de médicament , Acide fusidique , Moxifloxacine , Nanofibres , Pyridones , Cicatrisation de plaie , Pied diabétique/traitement médicamenteux , Pied diabétique/thérapie , Nanofibres/composition chimique , Animaux , Moxifloxacine/administration et posologie , Moxifloxacine/pharmacologie , Moxifloxacine/composition chimique , Moxifloxacine/pharmacocinétique , Cicatrisation de plaie/effets des médicaments et des substances chimiques , Antibactériens/composition chimique , Antibactériens/pharmacologie , Antibactériens/administration et posologie , Antibactériens/pharmacocinétique , Pyridones/composition chimique , Pyridones/pharmacologie , Pyridones/pharmacocinétique , Pyridones/administration et posologie , Acide fusidique/administration et posologie , Acide fusidique/pharmacologie , Acide fusidique/composition chimique , Acide fusidique/pharmacocinétique , Rats , Mâle , Diabète expérimental , Povidone/composition chimique , Rat Sprague-DawleyRÉSUMÉ
This study aimed to develop a novel Gelatin silver oxide material for releasing nitric oxide bionanocomposite wound dressing with enhanced mechanical, chemical, and antibacterial properties for the treatment of diabetic wounds. The gelatin- silver oxide nanoparticles (Ag2O-NP) bio nanocomposite was prepared using chitosan and gelatin polymers incorporated with silver oxide nanoparticles through the freeze-drying method. The samples were characterized using scanning electron microscopy (SEM) and X-ray diffraction (XRD) analysis. Results showed that the Ag2O-NP nanoparticles increased porosity, decreased pore size, and improved elastic modulus. The Ag2O-NP wound dressing exhibited the most effective antibacterial properties against Staphylococcus aureus and Escherichia coli. Among the samples, the wound dressing containing silver oxide nanoparticles demonstrated superior physical and mechanical properties, with 48% porosity, a tensile strength of 3.2 MPa, and an elastic modulus of 51.7 MPa. The fabricated wound dressings had a volume ratio of empty space to total volume ranging from 40% to 60%. In parallel, considering the complications of diabetes and its impact on the vascular system, another aspect of the research focused on developing a per2mediated wound dressing capable of releasing nitric oxide gas to regenerate damaged vessels and accelerate diabetic wound healing. Chitosan, a biocompatible and biodegradable polymer, was selected as the substrate for the wound dressing, and beta-glycerophosphate (GPß), tripolyphosphate (TPP), and per2mediated alginate (AL) were used as crosslinkers. The chitosan-alginate (CS-AL) wound dressing exhibited optimal characteristics in terms of hole count and uniformity in the scanning electron microscope test. It also demonstrated superior water absorption (3854%) and minimal air permeability. Furthermore, the CS-AL sample exhibited an 80% degradation rate after 14 days, indicating its suitability as a wound dressing. The wound dressing was loaded with S-nitrosoglutathione (GSNO) powder, and the successful release of nitric oxide gas was confirmed through the grease test, showing a peak at a wavelength of 540 nm. Subsequent investigations revealed that the treatment of human umbilical vein endothelial cells (HUVECs) with high glucose led to a decrease in the expression of PER2 and SIRT1, while the expression of PER2 increased, which may subsequently enhance the expression of SIRT1 and promote cell proliferation activity. However, upon treatment of the cells with the modified materials, an increase in the expression of PER2 and SIRT1 was observed, resulting in a partial restoration of cell proliferative activity. This comprehensive study successfully developed per2-mediated bio-nanocomposite wound dressings with improved physical, mechanical, chemical, and antibacterial properties. The incorporation of silver oxide nanoparticles enhanced the antimicrobial activity, while the released nitric oxide gas from the dressing demonstrated the ability to mitigate vascular endothelial cell damage induced by high glucose levels. These advancements show promising potential for facilitating the healing process of diabetic wounds by addressing complications associated with diabetes and enhancing overall wound healing.
Sujet(s)
Bandages , Escherichia coli , Gélatine , Monoxyde d'azote , Composés de l'argent , Cicatrisation de plaie , Gélatine/composition chimique , Cicatrisation de plaie/effets des médicaments et des substances chimiques , Monoxyde d'azote/métabolisme , Composés de l'argent/composition chimique , Composés de l'argent/pharmacologie , Humains , Escherichia coli/effets des médicaments et des substances chimiques , Antibactériens/pharmacologie , Staphylococcus aureus/effets des médicaments et des substances chimiques , Chitosane/composition chimique , Chitosane/pharmacologie , Nanoparticules métalliques/composition chimique , Porosité , Pied diabétique/thérapie , Pied diabétique/traitement médicamenteux , Nanoparticules/composition chimique , OxydesRÉSUMÉ
BACKGROUND: Diabetic foot ulcers in developing countries often become infected. The healthcare systems are often not equipped to conduct the culture and the sensitivity tests required for prescribing a targeted antibiotic treatment for diabetic foot infection (DFI). METHODS: We evaluate antibiotic stewardship programmes for DFIs, at every level of health care, with an emphasis on resource-poor settings such as in Africa. RESULTS: The management of DFI very often is adapted to the financial and practical realities of the resource-poor regions. The application of the point-of-care Gram stain of deep tissue samples is efficient, rapid, low cost and ubiquitously available. Upon the identification of the predominant pathogen in the Gram stain, a semi-quantitative preemptive antibiotic treatment can be started in accordance with the World Health Organization Aware, Watch and Restrict Essential Medicine List. This list is catered to every country and is a powerful tool. However, some basic knowledge of the local microbiological epidemiology is necessary to choose the most appropriate agent. We report our experience on using the rapidly available Gram stain for narrowing the preemptive choice of listed antibiotic agents, as an economic tool for antibiotic stewardship in DFIs. CONCLUSIONS: In the practical and resource-saving management of DFI, the 'therapeutic' use of Gram stains is not common in resource-rich countries but should be added to the arsenal of the general efforts for antibiotic stewardship.
Sujet(s)
Antibactériens , Gestion responsable des antimicrobiens , Pays en voie de développement , Pied diabétique , Pied diabétique/traitement médicamenteux , Pied diabétique/microbiologie , Humains , Antibactériens/administration et posologie , Antibactériens/usage thérapeutique , Chlorure de méthylrosanilinium , PhénazinesRÉSUMÉ
Diabetic wounds present a significant global health challenge exacerbated by chronic hyperglycemia-induced oxidative stress, impeding the natural healing process. Despite various treatment strategies, diabetic foot ulceration lacks standardized therapy. Ferulic acid (FA), known for its potent antidiabetic and antioxidant properties, holds promise for diabetic wound management. However, oral administration of FA faces limitations due to rapid oxidation, stability issues, and low bioavailability. The topical application of FA-loaded chitosan nanoparticles (FA-CSNPs) has emerged as a promising approach to overcome these challenges. Here, we report the development of a sustained-release formulation of FA-CSNPs within a hydrogel matrix composed of Chitosan and gelatin. The FA-CSNPs were synthesized using the ionic gelation method andoptimized through a Central Composite Design (CCD) approach. Characterization of the optimized nanoparticles revealed spherical morphology, a particle size of 56.9 ± 2.5 nm, and an impressive entrapment efficiency of 90.3 ± 2.4 %. Subsequently, an FA-CSNPs-loaded hydrogel was formulated, incorporating chitosan as a gelling agent, gelatin to enhance mechanical properties and cell permeation, and glutaraldehyde as a cross-linker. Comprehensive characterization of the hydrogel included pH, moisture loss, porosity, swelling index, rheology, water vapor transmission rate (WVTR), SEM, TEM, invitro drug release studies, antioxidant activity, antibacterial efficacy, cell cytotoxicity, cell migration studies on L929 fibroblast cell line, and stability studies. The stability study demonstrated negligible variations in particle size, zeta potential, and entrapment efficiency over 60 days, ensuring the stable nature of nanoparticles and hydrogel. This innovative delivery approach embedded within a hydrogel matrix holds significant promise for enhancing the therapeutic efficacy of FA-CSNPs-hydrogel in diabetic wound healing applications.
Sujet(s)
Chitosane , Acides coumariques , Pied diabétique , Hydrogels , Nanoparticules , Cicatrisation de plaie , Chitosane/composition chimique , Acides coumariques/administration et posologie , Acides coumariques/composition chimique , Acides coumariques/pharmacologie , Nanoparticules/composition chimique , Hydrogels/composition chimique , Cicatrisation de plaie/effets des médicaments et des substances chimiques , Pied diabétique/traitement médicamenteux , Antioxydants/administration et posologie , Antioxydants/pharmacologie , Antioxydants/composition chimique , Antioxydants/pharmacocinétique , Taille de particule , Animaux , Systèmes de délivrance de médicaments/méthodes , Humains , Libération de médicament , Gélatine/composition chimique , Préparations à action retardée/administration et posologie , Hypoglycémiants/administration et posologie , Hypoglycémiants/composition chimique , Hypoglycémiants/pharmacologie , Souris , Vecteurs de médicaments/composition chimique , Lignée cellulaire , Fibroblastes/effets des médicaments et des substances chimiquesRÉSUMÉ
Skin and soft tissue infections (SSTIs), and particularly diabetic-related foot infections (DFI), present diagnostic and therapeutic complexities, often leading to severe complications. This study aims to evaluate the in vitro efficacy of cefditoren and amoxicillin/clavulanic acid against typical DFI pathogens. Clinical samples from 40 patients with mild SSTIs were analyzed, revealing a predominance of Staphylococcus spp. and Streptococcus spp. species. Cefditoren exhibited activity against 90% of isolates, with superior potency over amoxicillin/clavulanic acid. These findings underscore the utility of cefditoren in empirical treatment of DFI, although a larger sample size would be desirable for further validation.
Sujet(s)
Association amoxicilline-clavulanate de potassium , Antibactériens , Céphalosporines , Pied diabétique , Tests de sensibilité microbienne , Humains , Pied diabétique/traitement médicamenteux , Pied diabétique/microbiologie , Antibactériens/usage thérapeutique , Association amoxicilline-clavulanate de potassium/usage thérapeutique , Céphalosporines/usage thérapeutique , Streptococcus/effets des médicaments et des substances chimiques , Infections des tissus mous/traitement médicamenteux , Infections des tissus mous/microbiologie , Mâle , Femelle , Staphylococcus/effets des médicaments et des substances chimiques , Adulte d'âge moyenRÉSUMÉ
BACKGROUND: Diabetic foot ulcers (DFU) is the most serious complication of diabetes mellitus, which has become a global health problem due to its high morbidity and disability rates and the poor efficacy of conventional treatments. Thus, it is urgent to identify novel molecular targets to improve the prognosis and reduce disability rate in DFU patients. RESULTS: In the present study, bulk RNA-seq and scRNA-seq associated with DFU were downloaded from the GEO database. We identified 1393 DFU-related DEGs by differential analysis and WGCNA analysis together, and GO/KEGG analysis showed that these genes were associated with lysosomal and immune/inflammatory responses. Immediately thereafter, we identified CLU, RABGEF1 and ENPEP as DLGs for DFU using three machine learning algorithms (Randomforest, SVM-RFE and LASSO) and validated their diagnostic performance in a validation cohort independent of this study. Subsequently, we constructed a novel artificial neural network model for molecular diagnosis of DFU based on DLGs, and the diagnostic performance in the training and validation cohorts was sound. In single-cell sequencing, the heterogeneous expression of DLGs also provided favorable evidence for them to be potential diagnostic targets. In addition, the results of immune infiltration analysis showed that the abundance of mainstream immune cells, including B/T cells, was down-regulated in DFUs and significantly correlated with the expression of DLGs. Finally, we found latamoxef, parthenolide, meclofenoxate, and lomustine to be promising anti-DFU drugs by targeting DLGs. CONCLUSIONS: CLU, RABGEF1 and ENPEP can be used as novel lysosomal molecular signatures of DFU, and by targeting them, latamoxef, parthenolide, meclofenoxate and lomustine were identified as promising anti-DFU drugs. The present study provides new perspectives for the diagnosis and treatment of DFU and for improving the prognosis of DFU patients.
Sujet(s)
Pied diabétique , Lysosomes , Humains , Lysosomes/génétique , Lysosomes/métabolisme , Lysosomes/effets des médicaments et des substances chimiques , Pied diabétique/génétique , Pied diabétique/traitement médicamenteux , Pied diabétique/anatomopathologie , RNA-Seq , Analyse sur cellule unique/méthodes , Analyse de profil d'expression de gènes , Pronostic , Mâle , Femelle , Apprentissage machine , Analyse de l'expression du gène de la cellule uniqueRÉSUMÉ
INTRODUCTION: To assess the efficacy of a chitosan-based gel (ChitoCare) for the treatment of non-healing diabetic foot ulcers (DFUs). RESEARCH DESIGN AND METHODS: Forty-two patients with chronic DFUs were randomized to the ChitoCare or placebo gel for a 10-week treatment period and 4-week follow-up. The primary study end point was the rate of complete wound closure at week 10, presented as relative rate. RESULTS: Thirty patients completed the 10-week treatment and 28 completed the 4-week follow-up. The ChitoCare arm achieved 16.7% complete wound closure at week 10 vs 4.2% in the placebo arm (p=0.297), 92.0% vs 37.0% median relative reduction in wound surface area from baseline at week 10 (p=0.008), and 4.62-fold higher likelihood of achieving 75% wound closure at week 10 (p=0.012). Based on the results of the Bates-Jensen Wound Assessment Tool, the wound state at week 10 and the relative improvement from the baseline were significantly better (median 20 vs 24 points, p=0.018, and median 29.8% vs 3.6%, p=0.010, respectively). CONCLUSIONS: ChitoCare gel increased the rate of the DFU healing process. Several secondary end points significantly favored ChitoCare gel. TRIAL REGISTRATION NUMBER: NCT04178525.